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Background: Whether used for pain management or recreation, opioids have a number of adverse effects
including hormonal imbalances. These imbalances have been reported to primarily involve testosterone
and affect bothmales and females to the point of interfering with successful treatment and recovery. We
conducted a systematic reviewandmeta-analysis to determine the extent that opioids affect testosterone
levels in both men and women, which may be relevant to improved treatment outcomes for opioid
dependence and for pain management.
Methods:Wesearched PubMed, EMBASE, PsycINFO, and CINAHL for relevant articles and included studies
that examined testosterone levels in men and women while on opioids. Data collection was completed
in duplicate.
Results: Seventeen studieswith2769participants (800opioidusers and1969 controls) fulﬁlled the review
inclusion criteria; 10 studieswere cross-sectional and sevenwere cohort studies. Results showed a signif-
icant difference in mean testosterone level in men with opioid use compared to controls (MD=−164.78;
95% CI: −245.47, −84.08; p<0.0001). Methadone did not affect testosterone differently than other opi-
oids. Testosterone levels in women were not affected by opioids. Generalizability of results was limited
due to high heterogeneity among studies and overall low quality of evidence.
Conclusions: Our ﬁndings demonstrated that testosterone level is suppressed in men with regular opi-
oid use regardless of opioid type. We found that opioids affect testosterone levels differently in men
than women. This suggests that opioids, including methadone, may have different endocrine disruption
mechanisms in men and women, which should be considered when treating opioid dependence.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC Supplementary materials for this article can be found by accessing the online version
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. Introduction
Opioids refer to a class of natural and synthetic drugs that
re used for pain management and opioid dependency (Fornasari,
012). They exert their analgesic effects by binding to opioid recep-
ors in the brain and spinal cord to inhibit neurotransmitter release
Mansour et al., 1987), causing both a reduction in neurotrans-
ission and an inhibition of sensory neurons responsible for pain
ensation. However, opioids also act on the respiratory control cen-
ers in the brain to cause a reduction in respiratory function, and
hey promote a reduction in gastrointestinal motility through their
ction in the digestive tract (Narita et al., 2001; Zhang et al., 2008).
hen taken appropriately and in recommended dosages, opioids
re effective for acute pain relief and management of chronic pain,
owever theyhavenumerouspotential side effects, including seda-
ion, nausea, drowsiness, and constipation (Baumann, 2009). Other
ide effects include decreases in sexual function, bone deteriora-
ion, hair loss, immunodeﬁciency, and pain sensitivity (Benyamin
t al., 2008; Hallinan et al., 2008). Opioids are also known to act on
ndocrine system function, producing hormonal imbalances that
ay lead to additional serious adverse effects (Katz and Mazer,
009).
Testosterone is a sex steroid that is controlled by the
ypothalamic–pituitary–gonadal (HPG) axis andproduced through
series of hormonal activations, which include the gonadotropin-
eleasing hormone (GnRH), luteinizing hormone (LH), and
ollicle-stimulating hormone (FSH). Alterations in testosterone
oncentration caused by exogenous substances such as opioids can
ave signiﬁcant effects on mood, stress reactivity, aggression, and
exual drive (Borjesson et al., 2011; Kosten and Ambrosio, 2002;
mith and Elliott, 2012). It is speculated that chronic opioid use
eads to suppression of GnRH, which indirectly lowers production
f testosterone (Katz and Mazer, 2009).
In the case of opioid use disorder, testosterone suppression has
een documented in opioid-dependent samples (Azizi et al., 1973;
endelson et al., 1975a, 1975b, 1984; Wang et al., 1978) as well
s patients undergoing methadone maintenance treatment (MMT;
liesener et al., 2005; Cofrancesco et al., 2006; Cushman, 1973).
ethadone is a synthetic opioid used to manage opioid use disor-
sometimes take years (Mattick et al., 2009). The consequences of
testosterone suppression in this particular sample of opioid users
may hinder their treatment initiation, maintenance, and recovery.
The incidence of opioid-induced testosterone suppression in
women is less commonly examined in the literature. However,
a disturbance in female sex hormone levels may also cause
the changes that are typically seen in men, and in samples of
methadone-treated patients, may lead to poor outcomes and
increased risk of relapse.
Based on a review of opioid use and the endocrine system, Katz
and Mazer (2009) suggest that all opioids suppress testosterone.
Studies on individuals with opioid use disorders, methadone-
treated patients, and opioid users for chronic pain alike all showed
signiﬁcant suppression of testosterone. However, the extent of
testosterone suppression was not measured quantitatively. A non-
systematic narrative literature review showed similar conclusions
(Elliott et al., 2011).
Although previous ﬁndings support that all opioids suppress
testosterone, direct comparisons of testosterone levels among dif-
ferent opioids have not been performed to date. It is possible that
some opioids affect testosterone more than others, which would
be useful in choosing a particular treatment course. Additionally,
having information on testosterone level in opioid users compared
to the clinically normal rangeswould be helpful for healthcare pro-
fessionals to determine if this reduction in testosterone is clinically
signiﬁcant and when to initiate treatment of its associated symp-
toms.
These reviews demonstrate that there is a growing interest
in this particular topic as a result of increased rates of opioid
use and it is likely that additional studies have been conducted
since these reviews were published. There is also a lack of quan-
tiﬁable data to support the effect of opioids on testosterone,
which will be appropriately estimated using a summary statis-
tic derived from a meta-analysis of studies that include small
samples. Furthermore, examination of the effect of opioids on
testosterone levels in women has yet to be completed, and stud-
ies that include samples of women are generally small in this
particular area of study, therefore a meta-analysis will provide
a larger estimate of effect. The quality of the literature alsoer and withdrawal symptoms in substitute opioid therapy (SOT;
attick et al., 2009). Treatment with methadone incorporates a
arm-reduction approach and involves maintaining patients on a
tabilized dose of methadone while slowly tapering off, which canneeds to be evaluated to highlight problematic areas for future
research and improvement. Hence, the need for a systematic
review with updated data that can be combined statistically in a
meta-analysis.
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Table 1
Search strategy.
Electronic database Search terms
MEDLINE 1. “analgesics, opioid” [Title/Abstract] OR
n=15 2. “methadone” [MeSH Major Topic] AND
3. “testosterone” [MeSH Major Topic]
“human” [MeSH Term]
EMBASE 1. *opiate/
n=27 2. *opiate agonist/
3. methadone/
4. testosterone/
5. 1 or 2
6. 3 and 4 and 5
Limit 6 to human
PsycINFO 1. *opiates/
n=6 2. *narcotic agonists/
3. *methadone/
4. exp Testosterone/
5. 1 or 2 or 3
6. 4 or 5
Limit 6 to human
CINAHL 1. MM “analgesics, opioid” AND
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Total; n=50
The main objective of this systematic review and meta-analysis
s to examine the association between opioids and testosterone
evels and provide a summary estimate of themagnitude of testos-
erone suppression. Speciﬁcally, we aim to: (1) determine whether
en receiving long-term opioids have low testosterone levels,
ompared to clinical reference ranges; (2) determine whether
omen receiving long-term opioids have low testosterone levels,
ompared to clinical reference ranges; (3) determine if testosterone
uppression varies by the type of opioid use, more speciﬁcally
ethadone versus other opioids; and (4) generate clinically rel-
vant evidence through a critical review of the literature.
. Methods
.1. Search strategy
This review adhered to an a priori designed protocol that is available upon
nquiry.Wesystematically searchedMEDLINE, EMBASE, PsycINFO, andCINAHLelec-
ronic databases from inception to September 19, 2014 for relevant articles. We
mplemented varying combinations of search terms to reﬂect differences in index-
ng among databases. The search was not restricted by language limitations. The
omplete search strategy can be found in Table 1. We manually reviewed reference
ists of included studies for relevant citations that may not have been picked up by
ur search strategybutwedidnot review the ‘gray literature’ includingdissertations
nd conference proceedings.
.2. Inclusion and exclusion criteria
The inclusion criteria consisted of observational studies (i.e. cohort, cross-
ectional, or case–control) or randomized controlled trials (RCTs) that measured
estosterone levels in populations of opioid users, including men and women. We
id not limit studies to type or purpose of opioid use (i.e. recreational or thera-
eutic) or apply any age, ethnicity, or geographic setting limitations. The primary
utcome of this review is testosterone level. There were no restrictions based on
utcome measurement, such as plasma or serum testosterone, and free, bound, or
otal testosterone. We excluded studies that included participants on testosterone
eplacement therapy.
.3. Data screening and extraction
We screened all citations and abstracts retrieved from the search strategy and
dentiﬁed articles for full-text extraction. Two authors (MB and HB) performed the
iterature search, screening, and data extraction independently; disagreements at
ny phase of the review process were resolved by discussion or in the case where
consensus was not reached, a third independent rater (ZS) determined eligibility.
e recorded the reasons for exclusion and the Kappa statistic for inter-rater agree-
ent of study inclusion at each stage of the screening process. Data were extracted
rom the studies in duplicate using a pilot-tested data extraction form. In the caseDependence 149 (2015) 1–9 3
where a study previously conducted by the current review authors was included, a
third reviewerwhowas unrelated to either paper veriﬁed the data extraction of that
particular study.We collected data on the following variables: study characteristics
(author, journal, year and place of publication), study design, sample size, age, sex,
opioid dose, testosterone level (free and total), time of blood draw, and statistical
analyses performed. We used the grading of recommendations, assessment, devel-
opment, and evaluation (GRADE) framework (Guyatt et al., 2011) to rate the quality
of evidence of studies included in this review.
2.4. Statistical analysis
For the meta-analysis, we employed a random effects model, which assumes
variation between studies and their respective effect sizes. We used mean differ-
ence (MD) to establish the overall effect size of the difference in mean testosterone
levels between opioid users and controls in each of the studies reviewed and have
presented these in a forest plot. The analysiswas performed separately by sex due to
the large variance in testosterone levels betweenmen andwomen.Weplanned sub-
group analyses by opioid type (methadone for opioid dependence versus opioids for
other conditions). We reported the results using 95% conﬁdence intervals (CI) and
performed all statistical analyses using STATA (StataCorp, 2009) andmeta-analyses
using Review Manager 5.2 (The Cochrane Collaboration, London, UK). This system-
atic review is reported according to the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009).
3. Results
Of the50articles retrieved fromthe initial searchanda thorough
screen of the reference lists, 17 studieswere included in the review
(Fig. 1); seven cohort and 10 cross-sectional studies. Studies were
excluded at each stage of screening for reasons pertaining to incor-
rect outcome of interest, failure to include appropriate comparison
group, and lackofprimary research; four studies excludedafter title
search, 25 studies excluded in the abstract screen, and three studies
excluded after full-text screen. Inter-rater agreement was 0.7, 0.4,
and 0.4 for the title, abstract, and full-text screen, respectively. Ini-
tial disagreements at the abstract and full-text screen stages were
later resolved by consensus, whereby the majority of studies were
included to undergo screening at the next stage.
3.1. Study characteristics
A detailed description of study characteristics is presented
in Table 2. A total of 800 opioid users were included in the
studies, the majority of whom were men (n=646) and 1969
controls (referring to the comparator group in the context of
this review). Age of the individuals included in these studies
varied from 17 to 58 years with a mean age >30 years for
most studies. Study samples reported general opioid dependence
(n=3), heroin dependence (n=5), methadone maintenance (n=7),
buprenorphine maintenance (n=1), heroin maintenance (n=1),
levoacetylmethadolmaintenance (n=1), and opioid use for chronic
pain (n=4). Daily opioid dose was highly variable among stud-
ies; 0.5–40mg morphine equivalent daily dose and 40–15mg
methadone. Testosterone levels varied from 100 to 700ng/dL
(3.5–24.3nmol/L) in men and from 26 to 55ng/dL (0.9–1.9nmol/L)
in women. Duration of opioid use ranged from months to years,
with a minimum of 3 months and maximum of 11 years; this was
referred to as ‘long-term’. Study publication years varied from1973
to 2014, however only ﬁve of the included studies were published
in the last 10 years.
3.2. Effect of opioid use on testosterone level in men
We were able to utilize data from 12 studies (including 17 indi-
vidual samples) to compare the difference in testosterone level in
menbetween opioid users and controls (Abs et al., 2000; Azizi et al.,
1973; Bawor et al., 2014; Blick et al., 2012; Bliesener et al., 2005;
Cushman, 1973; Daniell, 2002; Finch et al., 2000;Malik et al., 1992;
Mendelson et al., 1975a; Ragni et al., 1988; Wang et al., 1978).
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This systematic reviewandmeta-analysis sought to evaluate the
literature on the effect of opioid use on testosterone levels in menFig. 1. Studies selected for inclusion with number of
e found a signiﬁcantly reduced level of testosterone by a dif-
erence of 165ng/dL (5.7nmol/L) in men using opioids (n=607)
ompared to controls (n=1417) (MD=−164.78; 95% CI: −245.47,
84.08; p<0.0001) (Table 3, Fig. 2).
Three other studies were not included in the meta-analysis
ecause they did not use a control group for comparison, rather
hey drew comparisons to clinical reference ranges of testosterone
Rajagopal et al., 2003) or utilized a within-subjects cohort design
n which the participants had their testosterone levels measured
nd compared at different time points (Mendelson et al., 1984;
oberts et al., 2002). These individual ﬁndings, however, did show
igniﬁcant reductions in testosterone in opioid users.
.3. Effect of opioid use on testosterone level in women
We were able to combine the results of two studies assessing
estosterone level in women opioid users in a meta-analysis. There
as no signiﬁcant effect of opioids on testosterone level in opioid-
singwomen (n=121) compared to controls (n=512) (MD=−6.17;
5% CI: −39.87, 27.54; p=0.72) (Table 3, Fig. 3).
.4. Effect of opioid type on testosterone level in menWe were interested in determining whether certain opioids
educe testosterone levels differently than others, especially those
sed for substitute opioid therapy. We performed a sub-groups included after each stage of the screening process.
analysis using groups of methadone maintenance samples and
all other opioids. Although testosterone levels were lower
among the methadone-treated group (MD=−181.12; 95% CI:
−300.20,−62.05;p=0.003) compared to thenon-methadonegroup
(MD=−154.95; 95% CI: −243.45, −66.45; p=0.0006), this differ-
ence was not signiﬁcant.
3.5. GRADE quality of evidence
We evaluated our conﬁdence in these ﬁndings using the GRADE
framework (Guyatt et al., 2011). We found that the overall qual-
ity of evidence was low, mainly due to a serious risk of bias and
inconsistency within the literature, despite the presence of strong
associations among outcomes. Please refer to the Supplementary
Material for detailed GRADE ratings (Table S11) and for funnel plots
assessing publication bias (Figs. S1 and S22).
4. Discussion1 Supplementary material can be found by accessing the online version of this
paper.
2 Supplementary material can be found by accessing the online version of this
paper.
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Table 2
Study characteristics.
Author (year) Study design Participants (n) Sex Age (yrs);
mean (SD/SE)
or range
(min–max)
Daily opioid
dose
Route of
administration
Testosterone
(ng/dL); mean
(SD)
p-value
(difference
between
groups)
Abs et al. (2000) Cohort CP (29) M 48.4 (SD 11.0) 4.8mg ME (SD
3.2)a
Intrathecal 198.9 (149.9) <0.001
Control (11) 54.2 (SD 14.0) – – 443.8 (126.8)
Azizi et al. (1973) Cross-sectional MMT (6) M 17–58 60–140mg Oral 340 (110) <0.001b
HD (16) 17–58 60–140mg NR 440 (320) <0.02b
Control (25) 17–58 – – 700 (290)
Bawor et al. (2014) Cross-sectional MMT (231) M (131) 38.3 (SD 11.0) 90.2mg (SD
65.6)
Oral M: 100.1 (72.2) <0.001b
F (100) 35.2 (SD 9.4) 83.3mg (SD
52.8)
Oral F: 36.6 (23.2) NSb
Control (783) M (287) 46.2 (SD 13.1) – – M: 414.7
(141.8)
F (496) 44.6 (SD 12.6) F: 25.9 (15.2)
Blick et al. (2012) Cohort OD (90) M 48.3 (SD 12.0) NR NR 280 (170) NS
Control (759) 52.6 (SD 12.2) – – 287 (149)
Bliesener et al.
(2005)
Cross-sectional MMT (37) M 37.5 (6.9) 88.4mg (SD
16.0)
Oral 280 (120) <0.000b
BUP (17) 34.7 (7.4) 11.2mg (SD
4.3)
Sublingual 510 (120) NS
Control (51) 35.2 (4.5) – – 490 (130)
Cofrancesco et al.
(2006)
Cohort MMT (33) F 36.3 NR Oral 29.7 0.030
Control (163) – – 36.0
Cushman (1973) Cohort MMT (54) M 35.0 (7.0) 91mg (SD 25) Oral 577 (284) NSb
HD (23) 33.0 (7.0) NR NR 523 (279) NSb
Control (16) 31.0 (8.0) – – 589 (246)
Daniell (2002) Cross-sectional OD (23) M 49.4 (30–78) 70–120mg
(avg range)
Oral 188.5 (193.4) <0.001
Control (27) 57.4 (40–67) – 449.1 (181.1)
Daniell (2008) Cross-sectional OD (21) F 39.3 (4.9) 20–30mg Oral 30.7 (21.5) <0.001
Control (16) 42.7 (3.5) – – 54.5 (10.3)
Finch et al. (2000) Cross-sectional CP (11) M 46.5 (SE 3.5) 0.5–40mg ME
(avg range)
Intrathecal 141.2 (105.1) 0.0032
Control (9) 49.0 (SE 6.0) – 351. 6 (138.3)
Malik et al. (1992) Cross-sectional HD (33) M 18–50 37.8ng/ml ME
(SE 5.2)
Smoking or
vapor
inhalation
376.3 (215.4) <0.005
Control (35) 29.8 (SE 3.3) – 630.4 (137.9)
Mendelson et al.
(1975a, 1975b)
Cohort MMT (14) M 22–47 80–150mg Oral 409.1 (181.9) <0.01b
HM (12) 22–47 40–100mg NR 227.5 (116.6) <0.01b
Control (16) 22–47 – – 622.7 (166.9)
Mendelson et al.
(1984)
Cohort LAAM (9) M 19–36 50–65mg Oral 683 (162) <0.05c
–
Ragni et al. (1988) Cross-sectional MMT (42) M 25.0 (SE 5.0) 40–60mg Oral 520 (190) NSb
HD (15) 23.0 (SE 6.0) Unknown NR 550 (120) NSb
Control (15) 30.0 (SE 6.0) – – 490 (110)
Rajagopal et al.
(2003)
Cross-sectional CP (20) M 50.1 (34–77) >200mg ME Oral Median: 140
(range 21–381)
NR
– –
Roberts et al.
(2002)
Cohort CP (10) M 52.4 (SE 4.0) 3.3mg ME (SD
0.6)
Oral or
intrathecal
115.3 (81.9) <0.0001c
Wang et al. (1978) Cross-sectional HD (54) M 34.6 (SE 1.5) >40ng/ml Smoking, vapor
inhalation, or
intravenously
521.6 (211.6) <0.005
Control (43) 34.6 (SE 1.5) – 657.1 (207.9)
Note: Some studies reported standard error (SE); these values have been transformed to standard deviation for consistency.
CP, chronic pain; HD, heroin dependence; OD, opioid dependence (general); BUP, buprenorphine maintenance; MMT, methadone maintenance; HM, heroin maintenance;
LAAM, levoacetylmethadol maintenance; M, male; F, female.
a Speciﬁed dose is combined for sample of men and women; it is not male-only like the other variables for that study.
a
p
a
l
bb Compared to control.
c Within subjects cohort: compared to when subjects were not using opioids.
nd women. We found that patients using opioids for therapeutic
urposes, medication-assisted addiction treatment, or as a drug of
buse and dependence have signiﬁcantly suppressed testosterone
evels compared to non-opioid users, and there was no difference
etween methadone, a commonly used substitute opioid therapy,and other types of opioids. This indicates that all opioids suppress
testosterone, regardless of drug type or indication of use.
This fact has signiﬁcant implications for all patients who are
prescribed long-term opioids. It is likely that men prescribed
methadone treatment for opioid use disorders already have low
6 M. Bawor et al. / Drug and Alcohol Dependence 149 (2015) 1–9
Table 3
Summary of meta-analysis results.
Group No. of studies Subjects; n Pooled MD
(95% CI)
I2% Summary of
differences
GRADE quality
of evidence
Opioid users Controls
Men
Methadone treatment 6 284 410 −181.12
(−300.20,
−62.05)
p=0.003
95
p<0.0001
Testosterone is
signiﬁcantly
lower in all
opioid users
compared to
controls
Lowa,b
Opioids (excluding methadone) 11 323 1007 −154.95
(−243.45,
−66.45)
p=0.0006
92
p<0.0001
Lowa,b
All opioids 17 607 1417 −164.78
(−245.47,
−84.08)
p<0.0001
96
p<0.0001
Lowa,c,d
Women
All opioids 2 121 512 −6.17 (−39.87,
27.54)
p=0.72
97
p<0.0001
No signiﬁcant
difference in
testosterone
between opioid
users and
controls
Very lowc,e
a Some studies did not adjust or control for potential confounders (age, BMI, duration of opioid use, opioid dose, smoking, etc.).
b Large mean difference in testosterone levels between opioid users vs. control (p<0.01).
c Signiﬁcant differences in patient populations and outcome measurements may limit generalizability.
(p=0
y attri
t
c
m
T
w
f
F
td Large mean difference of testosterone (159.08ng/dL) in opioid users vs. control
e High variability in direction andmagnitude of effect between studies, potentiall
estosterone levels. Based on clinical observations, one of the con-
erns that men with opioid dependence have regarding entry to
ethadone treatment is that their testosteronewill be suppressed.
estosterone deﬁciency is accompanied by symptoms of fatigue,
eakness, mood disturbances, and decrease in libido and sexual
unction, aswell as other conditions including erectile dysfunction,
ig. 2. Effect of opioid use on testosterone level in men. Caption: forest plot representing
reatment compared to other opioids..0002).
buted to differences in characteristics and sample size of patient vs. control groups.
and hypogonadism (Borjesson et al., 2011; Smith and Elliott, 2012).
Therefore, it is a common concern for men starting treatment with
methadone that they may experience testosterone suppression
effects due to methadone. It is important therefore that clinicians
treating opioid addiction disorders provide health education to
patients to inform them about potential hormonal side effects. It
the relationship between opioid use and testosterone in men using methadone for
M. Bawor et al. / Drug and Alcohol Dependence 149 (2015) 1–9 7
F prese
c
i
b
s
e
t
a
K
o
t
p
o
d
u
B
t
p
e
d
u
l
t
(
r
a
t
s
a
e
d
o
a
e
o
i
o
c
s
i
r
4
o
d
q
b
f
pig. 3. Effect of opioid use on testosterone level in women. Caption: forest plot re
ontrols across studies.
s also recommended that clinicians measure testosterone level
efore starting SOT and if they ﬁnd that testosterone is already
uppressed. Testosterone replacement therapy should be consid-
red carefully and provided when appropriate. It is expected that
reating testosterone deﬁciency symptoms will improve the over-
ll quality of life of patients (Daniell et al., 2006; Dazord et al., 1998;
atznelson et al., 2006) and potentially opioid addiction treatment
utcomes. Based on the current study ﬁndings, it is recommended
hat testosterone levels bemonitored inpatientsprescribedopioids
rior to treatment initiation andperiodically throughout the course
f treatment to allow for appropriate management of testosterone
eﬁciency in men.
Buprenorphine, a synthetic opioid similar to methadone, is also
sed in substitute opioid therapy, and was explored in a study by
liesener et al. (2005). Although testosterone levelswere greater in
he buprenorphine-treated group compared tomethadone-treated
atients and when compared to non-opioid users, these differ-
nces were not signiﬁcant (Bliesener et al., 2005). This ﬁnding
oes potentially highlight the need for further studieswith patients
ndergoing addiction treatment with buprenorphine that include
arger sample sizes, in order to clarify this effect.
Our review has conﬁrmed that all opioids suppress testos-
erone, which is consistent with previous reviews in the literature
Katz and Mazer, 2009; Smith and Elliott, 2012). However, this
eview is the ﬁrst to synthesize this information in a meta-analysis
nd provided a statistical estimate of the magnitude of testos-
erone deﬁciency. Our ﬁndings demonstrate that testosterone is
uppressed by almost 50% in some men and is far below the
verage clinical reference ranges. We did not observe the same
ffect in women, which suggests that men and women have
ifferent mechanisms of hormonal disturbance caused by opi-
ids. This review can potentially inform both healthcare providers
nd individuals prescribed opioids about the endocrine disrupting
ffects of opioid use to make informed decisions about treatment
ptions andother alternatives to be considered. Non-steroidal anti-
nﬂammatory drugs (NSAIDs) and chiropractic care are additional
ptions for pain relief that can prevent the testosterone deﬁciency
aused by opioids. Future studies are required to address whether
upplementation with testosterone is an effective approach to the
mprovement of quality of life and addiction treatment in men
eceiving opioids.
.1. GRADE quality of evidence
We used the GRADE framework (Guyatt et al., 2011) to evaluate
ur conﬁdence in the estimates derived from themeta-analysis and
etermined that the studies reported in the literature were of low
uality (see Table S13 of Supplementary Material for ratings).
The most prominent concerns among the studies were risk of
ias and confounding. Some studies had adjusted for potential con-
ounders by considering certain factors in their analyses such as
3 Supplementary material can be found by accessing the online version of this
aper.nting the difference in testosterone levels between women who use opioids and
age (Malik et al., 1992) and methadone dose (Daniell, 2002); how-
ever the remaining studies either did not take into consideration
such factors or failed to report them. Data on duration of opioid
use, smoking, concurrent medications, or polysubstance use were
collected in some studies but not accounted for when measuring
testosterone level. Also, there was often no mention of whether
or not participants were undergoing any testosterone replacement
therapy at the time of study, or whether other hormonal medica-
tions were being used. This also raises the issue of lack of reporting
standards among studies in this ﬁeld. The majority of studies were
performed between 1980 and 2000, when standards for repor-
ting studies were different than today. After the introduction of
the Consolidated Standards of Reporting Trials (CONSORT) state-
ment and later its multiple extensions in 1996, as well as the
gradual uptake of these statements by journals, reporting stan-
dards have improved (Samaan et al., 2013). However, important
piecesof information related tomethodology, statistics, or outcome
measurements remain unknown in older studies included in this
review, thus impacting the quality assessment.
We noticed a high level of heterogeneity and variability among
studies which may be attributed to differences in outcome mea-
surements (i.e. free vs. total vs. bound; plasma vs. serum, different
assay methods). This was especially prominent in the studies with
women opioid users, where the two studies had an opposite direc-
tion of effect (Bawor et al., 2014; Daniell, 2008). This may be due
to small sample sizes of individual studies, suggesting that they
may not have the power to accurately detect this difference in
the outcome or it could be explained by some unknown factors
that inﬂuenced the control groups. Additionally, in this review, we
included samples where participants were dependent on opioids,
had serious health concerns, and suffered from lack of adequate
healthcare. We also had samples of patients with chronic pain
consuming prescription opioids whose doses were regulated and
carefully monitored, and taken under safe conditions. Characteris-
tics of these populations may differ, and although the results were
consistent among both types of samples, they may have limited
comparability in terms of how generalizable the overall summary
ﬁnding is.
Our overall conﬁdence in the estimates is therefore quite low,
however our meta-analysis generally showed a consistent large
effect size across multiple studies, which does provide evidence
for testosterone deﬁciency associated with opioid use.
4.2. Strengths and limitations
Thiswasa systematically conducted reviewwith rigorous statis-
tics and a largemeta-analysis that provided a quantiﬁable estimate
of the effect of opioid use on testosterone levels. We observed this
relationship amongmen aswell aswomen,which is not commonly
reported.Wealso compared testosterone levels amongopioidusers
being treatedwithmethadone for addiction and opioid use (includ-
ing prescription opioids) for conditions other than addiction. A
thorough evaluation of the status of literature was also performed.
As evaluated by the GRADE framework, the quality of evidence
in thisﬁeldof study ispoor, and therefore the results summarized in
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his review should be interpreted with this consideration in mind.
owever, this review has brought to light the need for more up to
ate research using current hormone assay methods, appropriate
eporting, and rigorous methodology. It has also been successful in
dentifying the need for future examination into the effect of opi-
ids on testosterone levels in women. The lack of studies among
omen opioid users included in this review, as well as the small
ample sizes of these studies, poses a challenge in drawing ade-
uate conclusions of this association.
. Conclusion
Our systematic review and meta-analysis demonstrated that
estosterone levels are suppressed in men receiving opioids,
egardless of opioid type or indication of use. These ﬁndings may
ave important potential implications for treatment. Testosterone
evels are likely to already be signiﬁcantly lowered in patients with
history of opioid use. The results of this study can be used by
ealthcare professionals and patients themselves when choosing
o enter substitute opioid treatment for opioid dependence. It is
ecommended that testosterone levels are monitored at treatment
ntry as well as throughout the course of treatment, so that low
estosterone and related symptoms may be adequately treated.
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